{"id":"bismuth-potassium-citrate-placebo-capsules","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bismuth potassium citrate is a known anti-ulcer agent that can reduce gastric acid and provide cytoprotection, but this product is explicitly a placebo capsule used as a control in clinical trials. It contains no active drug and is designed to be indistinguishable from an active comparator for blinding purposes in Phase 3 studies.","oneSentence":"This is a placebo formulation containing bismuth potassium citrate with no active therapeutic mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:43:24.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bismuth placebo","Bismuth","Bismuth Potassium Citrate"],"phase":"phase_3","status":"active","brandName":"Bismuth potassium citrate placebo capsules","genericName":"Bismuth potassium citrate placebo capsules","companyName":"TenNor Therapeutics (Suzhou) Limited","companyId":"tennor-therapeutics-suzhou-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation containing bismuth potassium citrate with no active therapeutic mechanism. Used for Control arm in Phase 3 clinical trial (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}